-
Immatics NASDAQ:IMTX Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Location: Paul Ehrlich-Strasse 15, Baden Wuerttemberg, 72076, Germany | Website: immatics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
742.9M
Cash
158.1M
Avg Qtr Burn
-4.319M
Short % of Float
10.71%
Insider Ownership
22.17%
Institutional Own.
69.86%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ACTengine® IMA203 GEN1 (PRAME) Details Cancer, Solid tumor/s, Melanoma | Phase 3 Initiation | |
TCER® IMA402 (PRAME) Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
ACTengine® IMA203CD8 GEN2 (PRAME) Details Solid tumor/s, Cancer, Melanoma | Phase 1b Data readout | |
TCER® IMA401 (MAGEA4/8) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
ACTengine IMA201 Details Solid tumor/s, Cancer | Failed Discontinued | |
ACTengine IMA202 Details Cancer, Solid tumor/s | Failed Discontinued |